Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open-Label Pharmacokinetic of Oseltamivir in Healthy Obese Thai Adult Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01049763
Recruitment Status : Completed
First Posted : January 14, 2010
Last Update Posted : October 8, 2010
Sponsor:
Collaborator:
University of Oxford
Information provided by:
South East Asia Infectious Disease Clinical Research Network

Brief Summary:

This study is planned to characterize the pharmacokinetic properties of oseltamivir and the active product--oseltamivir carboxylate--in obesity in order to provide clinical guidance for the optimum oseltamivir treatment regimens for severe influenza. It is also a prompt response to a new era influenza plan along with recognition of growing numbers of obese persons.

The study findings will be available for a future management plan in dealing with this virus that is transmitted easily from person to person and has shown substantial antigenic changes over time.

The primary focus of statistical analysis is to verify the effect of obesity on oseltamivir/oseltamivir carboxylate pharmacokinetics as measured by oseltamivir carboxylate Cmax, AUC (0-12), AUC (0-24), C12, λz, and t1/2 and oseltamivir Cmax, AUC (0-12), and C12.


Condition or disease Intervention/treatment Phase
Healthy Drug: oseltamivir Phase 1

Detailed Description:

This is an open-label, cross-over, randomized pharmacokinetic study conducted in approximately 12 obese and 12 non obese adult subjects at one study center in Thailand.

Subjects will receive 2 regimens in a random sequence for 2 visits.

  1. Regimen A; 75 mg single dose.
  2. Regimen B; 150 mg single dose. All dosing will be supervised and documented. Subjects will have 2 hospitalizations to complete visit 2 and visit 3 in their assigned sequence within each. Each visit will require hospitalization for about 40 hours (2 nights and 2 days). The subject will be randomized to receive either regimen A or B on first admission (visit 2). Treatment allocation will be performed using computer-generated list of random permutations of AB sequence.

Subjects who received regimen A will receive regimen B on second admission and vice versa, with more than 3 days wash out period in between. Subjects will return to the study centre for a follow-up visit 7-10 days after completing the last dosing assessments or withdrawing from the study. The total duration of study participation will be approximately 4 weeks from screening through follow-up.

Assessment of the safety profile will be done after each admission by the investigating team before proceeding to the other regimen.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Phase I, Open-Label Study to Evaluate Potential Pharmacokinetic of Orally Administered Oseltamivir in Healthy Obese Thai Adult Subjects
Study Start Date : January 2010
Actual Primary Completion Date : September 2010
Actual Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Oseltamivir

Arm Intervention/treatment
Experimental: Regimen A
oseltamivir 75 mg single dose
Drug: oseltamivir
oseltamivir 150 mg single oral dose oseltamivir 75 mg single oral dose

Active Comparator: Regimen B
oseltamivir 150 mg single dose
Drug: oseltamivir
oseltamivir 150 mg single oral dose oseltamivir 75 mg single oral dose




Primary Outcome Measures :
  1. Oseltamivir carboxylate maximum concentration (OC Cmax) and area under the concentration curve 0-12h (OC AUC(0-12)) [ Time Frame: 12 hours ]

Secondary Outcome Measures :
  1. Oseltamivir maximum concentration at 12 hours (OS C12) Oseltamivir carboxylate area under the concentration curve 0-24 hours AUC(0-24)), concentration at 24 hours (C24), elimination rate constant (OC-λz), and elimination half life (t1/2) [ Time Frame: 1 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy as judged by a responsible physician with no abnormality identified on a medical evaluation including medical history and physical examination.
  • Males and Females aged between 18 years to 60 years.
  • BMI >30 kg/ m2 (BMI = body weight [BW] (kg)/height (m2)) for obese group, BMI 18-24.9 kg/ m2 (BMI = BW (kg)/height (m2)) for control group.
  • A female is eligible to enter and participate in this study if she is:

    • of non-childbearing potential including pre-menopausal females with documented (medical report verification) hysterectomy or double oophorectomy
    • or postmenopausal defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone levels >40 mIU/mL or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy
    • or of childbearing potential, has a negative serum pregnancy test at screening and prior to start the study drug in each period, and abstain from sexual intercourse or agrees to using effective contraceptive methods during the study until completion of the follow-up procedures
  • A male is eligible to enter and participate in this study if he: agrees to abstain from (or use a condom during) sexual intercourse with females of childbearing potential or lactating females; or is willing to use a condom/spermicide, during the study until completion of the follow-up procedures.
  • Read, comprehend, and write at a sufficient level to complete study-related materials.
  • Provide a signed and dated written informed consent prior to study participation.
  • Normal electrocardiogram (ECG) with QTc <450 msec.
  • Willingness and ability to comply with the study protocol for the duration of the trial.

Exclusion Criteria:

  • Females who are pregnant, trying to get pregnant, or are lactating.
  • The subject has evidence of active substance abuse that may compromise safety, pharmacokinetics, or ability to adhere with protocol instructions.
  • A positive pre-study hepatitis B surface antigen, positive hepatitis C antibody, or positive human immunodeficiency virus-1 (HIV-1) antibody result at screening.
  • Subjects with a personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or additional risk factors for torsades de points (heart failure, hypokalemia).
  • Subjects with a family history of sudden cardiac death.
  • A creatinine clearance <70 mL/min as determined by Cockcroft-Gault equation:

CLcr (mL/min) = (140 - age) * Wt / (72 * Scr) (multiply answer by 0.85 for females). Where age is in years, weight (wt) is in kg, and serum creatinine (Scr) is in units of mg/dL [Cockcroft, 1976].

  • History of alcohol or substance abuse or dependence within 6 months of the study: History of regular alcohol consumption averaging >7 drinks/wk for women or >14 drinks/wk for men. One drink is equivalent to 12 g alcohol = 5 oz (150 mL) of wine or 12 oz (360 mL) of beer or 1.5 oz (45 mL) of 80 proof distilled spirits within 6 months of screening.
  • Use of prescription or non-prescription drugs except paracetamol at doses of up to 2 grams/day, including vitamins, herbal and dietary supplements within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication until the completion of the follow-up procedure.
  • Use of live attenuated influenza vaccine, inactivated influenza vaccine, or any other antiinfluenza antiviral medications within 14 days prior to the first dose of investigational product.
  • The subject has participated in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 half lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of study medication.
  • The subject is unwilling to abstain from ingesting alcohol within 48 hours prior to the first dose of study medication until collection of the final pharmacokinetic sample during each regimen.
  • Subjects who have donated blood to the extent that participation in the study would result in more than 300 mL blood donated within a 30-day period.
  • Subjects who have a history of allergy to the study drug or drugs of this class, or a history of drug or other allergy that, in the opinion of the investigator, contraindicates participation in the trial. In addition, if heparin is used during pharmacokinetic sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.
  • Subjects with unstable medical conditions that, in the opinion of the investigator would compromise their participation in the trial
  • Those who, in the opinion of the investigator, have a risk of non-compliance with study procedures.
  • Lack of suitability for participation in this study, for any reason, in the opinion of the investigator.
  • AST or ALT >1.5 upper limit of normal (ULN)
  • Subjects with history of renal disease, hepatic disease, and/or cholecystectomy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01049763


Locations
Layout table for location information
Thailand
Mahidol-Oxford Tropical Medicine Research Unit Faculty of Tropical Medicine, Mahidol University Bangkok
Bangkok,, Thailand
Sponsors and Collaborators
South East Asia Infectious Disease Clinical Research Network
University of Oxford
Investigators
Layout table for investigator information
Principal Investigator: Podjanee Jittmala, MD Mahidol-Oxford Tropical Medicine Research Unit Faculty of Tropical Medicine, Mahidol University
Study Chair: Sasithon Pukrittayakamee, Professor Faculty of Tropical Medicine, Mahidol University Bangkok, Thailand
Study Chair: Pratap Singhasivanon, A/Professor Faculty of Tropical Medicine, Mahidol University Bangkok, Thailand
Study Chair: Nick White, Professor Mahidol-Oxford Tropical Medicine Research Unit Faculty of Tropical Medicine, Mahidol University Bangkok, Thailand
Study Chair: Nick Day, Professor Mahidol-Oxford Tropical Medicine Research Unit Faculty of Tropical Medicine, Mahidol University Bangkok, Thailand
Study Chair: Niklas Lindegardh, A/Professor Clinical Pharmacology Laboratory Faculty of Tropical Medicine, Mahidol University Bangkok, Thailand
Study Chair: Bob Taylor, MD Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University Bangkok, Thailand
Additional Information:
Publications:
Beckel MH. Factor affecting the storage of drug and other xenobiotics in adipose tissue. Adv Drug Res 1994; 25: 55-86.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dr. Podjanee Jittmala, Mahidol-Oxford Tropical Medicine Research Unit Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
ClinicalTrials.gov Identifier: NCT01049763    
Other Study ID Numbers: SEA 131
First Posted: January 14, 2010    Key Record Dates
Last Update Posted: October 8, 2010
Last Verified: October 2010
Keywords provided by South East Asia Infectious Disease Clinical Research Network:
obese adult
non obese healthy volunteers
oseltamivir carboxylate
pharmacokinetics
healthy volunteers
Additional relevant MeSH terms:
Layout table for MeSH terms
Oseltamivir
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action